Swenson Colin, Lapinel Nicole C, Ali Juzar
Division of Pulmonary, Allergy, Critical Care, and Sleep Medicine, Emory University, Atlanta, Georgia, USA.
Section of Pulmonary/Critical Care Medicine & Allergy/Immunology, Louisiana State University Health Sciences Center, New Orleans, Louisiana, USA.
Open Forum Infect Dis. 2020 Mar 2;7(4):ofaa079. doi: 10.1093/ofid/ofaa079. eCollection 2020 Apr.
Patients with complex lung disease treated with amikacin liposome inhalation suspension (ALIS) at 2 clinics in the United States were surveyed to assess the frequency and management of ALIS-associated respiratory adverse events. Most respondents experienced these events, but management through physician-guided measures (eg, bronchodilator use, oral rinses, and/or temporary dosing adjustments) resulted in symptomatic improvement.
在美国两家诊所接受阿米卡星脂质体吸入混悬液（ALIS）治疗的复杂肺部疾病患者接受了调查，以评估与ALIS相关的呼吸道不良事件的发生频率和处理情况。大多数受访者经历过这些事件，但通过医生指导的措施（如使用支气管扩张剂、口腔冲洗和/或临时调整剂量）进行处理后症状得到改善。
